This Review focuses on the epidemiology, pathogenesis and treatment of dyslipidaemia in patients with chronic kidney disease (CKD) and end-stage renal disease. The authors discuss emerging clinical data on the use of novel lipid-lowering agents and reappraise the 2013 KDIGO Guidelines for Lipid Management in CKD.
- Charles J. Ferro
- Patrick B. Mark
- Carmine Zoccali